Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
434.85 USD | -1.63% | -0.87% | +15.92% |
Sep. 07 | McKesson CEO Tyler Sells 3,938 Shares for $1.6 Million | MT |
Aug. 31 | MCKESSON CORPORATION : Ex-dividend day for | FA |
Financials (USD)
Sales 2024 * | 305 B | Sales 2025 * | 325 B | Capitalization | 59 632 M |
---|---|---|---|---|---|
Net income 2024 * | 3,461 M | Net income 2025 * | 3,642 M | EV / Sales 2024 * | 0,21x |
Net Debt 2024 * | 3,050 M | Net Debt 2025 * | 4,573 M | EV / Sales 2025 * | 0,20x |
P/E ratio 2024 * | 17,0x | P/E ratio 2025 * | 15,5x | Employees | - |
Yield 2024 * | 0,56% | Yield 2025 * | 0,61% | Free-Float | 48.47% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
1 day | -0.53% | ||
1 week | +0.87% | ||
Current month | +7.21% | ||
1 month | +4.40% | ||
3 months | +6.46% | ||
6 months | +24.70% | ||
Current year | +17.84% |
1 week
439.60
446.95

1 month
404.72
446.95

Current year
331.75
446.95

1 year
331.75
446.95

3 years
141.32
446.95

5 years
106.11
446.95

10 years
106.11
446.95

Managers | Title | Age | Since |
---|---|---|---|
Brian Tyler
CEO | Chief Executive Officer | 56 | 2019 |
Britt Vitalone
DFI | Director of Finance/CFO | 54 | 2018 |
Nancy Flores
CTO | Chief Tech/Sci/R&D Officer | 57 | 2020 |
Members of the board | Title | Age | Since |
---|---|---|---|
Brian Tyler
BRD | Director/Board Member | 56 | 2019 |
Maria Martinez
BRD | Director/Board Member | 65 | 2019 |
Donald Knauss
CHM | Chairman | 72 | 2022 |
Date | Price | Change | Volume |
---|---|---|---|
23-09-29 | 434.85 | -1.63% | 682 085 |
23-09-28 | 442.04 | -0.53% | 694,570 |
23-09-27 | 444.38 | +0.30% | 953,737 |
23-09-26 | 443.03 | -0.76% | 816,562 |
23-09-25 | 446.42 | +1.77% | 998,979 |
Delayed Quote Nyse, September 28, 2023 at 04:01 pm EDT
More quotes
McKesson Corporation specializes in pharmaceutical product distribution. The group also offers technological services to healthcare companies. Net sales break down by activity as follows:
- distribution of pharmaceutical products (80.4%);
- distribution of medical and surgical products (4.4%);
- other (1.5%): primarily technology services and software sales.
The remaining sales (13.8%) are from international activities.
Sector
Pharmaceuticals
Calendar
2023-11-01
- Q2 2024 Earnings Release
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
Sell
Buy

Mean consensus
BUY
Number of Analysts
15
Last Close Price
442.04USD
Average target price
474.23USD
Spread / Average Target
+7.28%
EPS Revisions
1st Jan change | Capi. (M$) | |
---|---|---|
+17.84% | 59 632 M $ | |
+14.22% | 21 630 M $ | |
-9.74% | 10 126 M $ | |
+15.68% | 8 970 M $ | |
+1.40% | 8 325 M $ | |
0.00% | 4 121 M $ | |
+23.75% | 4 034 M $ | |
-21.18% | 3 955 M $ | |
+45.18% | 3 577 M $ | |
+18.82% | 3 426 M $ |